Nexavar priority review for liver cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA grants priority review for Bayer/Onyx's Nexavar (sorafenib) sNDA for use in hepatocellular carcinoma, the firms announce Aug. 20. Completed in June, the submission is supported by data from the Phase III SHARP trial, which demonstrated that Nexavar extended overall survival by 44 percent in patients with liver cancer versus placebo. If approved, the multikinase inhibitor would be the first FDA-approved therapy for the treatment of liver cancer. The priority review designation sets the user fee date in February 2008. Nexavar was approved in December 2005 for the treatment of advanced kidney cancer (1Pharmaceutical Approvals Monthly January 2006, p. 3)...
You may also be interested in...
FDA’s 2005 New Molecular Entity Total: 18, Including Five In December
FDA clearance of Bayer/Onyx’ Nexavar oncologic Dec. 20, ahead of its Jan. 11, 2006 user fee goal date, helped the agency achieve a total of 18 new molecular entity approvals in 2005.
Supreme Court May Find Patent Board Judges Unconstitutionally Appointed But Favor Narrow Fix
During oral argument in the Arthrex case, several justices seemed to agree with the Federal Circuit that PTAB judges should have been appointed by the president. They could opt to get around the problem by enabling the PTO director to review all panel decisions.
Pro Beauty Association Opposing Fast-Tracked Bill To Deregulate Licensing In West Virginia
House Bill 2325, on a fast track in West Virginia, would bar the state’s Board of Barbers and Cosmetologists from regulating unlicensed individuals’ use or application of “generally available” cosmetic products for paying clients. PGA’s government affairs team provides detail.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: